Liquid biopsy-based cfDNA diagnostics are continuing to become an integral part of a patient’s journey. From early detection, clinical diagnosis, therapy selection, resistance detection and response and relapse monitoring.

The Agilent Technologies Engager will be focusing on the utilization of liquid biopsies in therapy selection, detection of biomarkers that cause resistance and continued response monitoring and how this can be used to advance novel biomarker discovery.

Exclusively designed for Biopharma Directors, Heads & VPs working in the liquid biopsy, companion diagnostics and clinical development space, this 2-hour networking event will be addressing how liquid biopsy-based cfDNA diagnostics are currently being applied from discovery all the way through to companion diagnostic development, and how they can lead to the advancement of additional combinational therapies as well as novel biomarkers for therapeutic development.

This is your opportunity to gain insights from industry leading experts from diagnostic development, therapeutic development, and academic research!

With an insightful panel discussion among key opinion leaders followed by complimentary appetizers and drinks, this is a date not to be missed!